@FierceMedDev: RTTNews: DSM To Buy US-based Kensey Nash For $360 Mln. Report | Follow @FierceMedDev
> Qiagen ($QIA) has joined the Point-of-Care Diagnostics Initiative launched by the Bill & Melinda Gates Foundation and Grand Challenges Canada to develop new molecular diagnostics technologies for the developing world. Release
> Medtronic ($MDT) is slashing about 220 positions from its cardiac rhythm management division, whose revenue plunged 9%, according to the company's most recent earnings release. Story
> Advanced Brain Monitoring is gearing up for the commercial launch of the company's Apnea Guard, a temporary oral device designed to treat snoring and sleep apnea for up to a month. Release
> Angioslide gained 510(k) clearance for its new 3X100mm Proteus device to great peripheral artery disease below the knee. Release
> A new medical device company is born: Personal Medical Corp., which will focus on women's health. Spun out of SRS Medical in Billerica, MA, the new startup will be run by former SRS CEO and founder Kevin Connolly. Release
> Nanosonics, an Australian company developing products to control infections, is raising money. Story (sub. req.)
> Medicare contractor Wisconsin Physician Service has approved Midwest reimbursement for Kinetic Concepts' Graftjacket regenerative tissue matrix to treat neuropathic diabetic foot ulcers. News
> Here's a definite milestone to think about. Spinal implant maker Vertebral Technologies is touting the 2,000th implant of its InterFuse interbody fusion device in the U.S. Release
Biotech News:
@FierceBiotech: Crazy or creative? MIT finance whiz suggests a twist on R&D funding drought: Bankroll it with risky derivatives Report | Follow @FierceBiotech
@JohnCFierce: Merck KGaA had already dumped the 2055 pact it had with Idera on safety concerns. Now it flunks Phase II. Finished. Item | Follow @JohnCFierce
@RyanMFierce: Ironic and idiotic. A call for open access to clinical trials data in a journal article locked behind a pay wall. Article | Follow @RyanMFierce
@MarkHFierce: OTC cranberry capsule gains medical device status in Europe as a cure for bladder infections. A first, it seems. Release | Follow @MarkHFierce
> Pharma giants offer up drug candidates for $20M NIH collaboration. Report
> Pressure on premiums in M&A push biotech prices higher. News
> Idera's troubled TLR program founders in PhII cancer study. More
Pharma Manufacturing News
@EricPFierce: Genzyme says the FDA and EMA have signed off a second fill-finish operation for a couple of drugs at the upgraded plant in Ireland. Report | Follow @EricPFierce
> Hospira says temporary production glitch affecting propofol supplies. More
> Workers killed in another API plant explosion. News
> Genzyme's $150M plant upgrade starts to pay off. Article
> Merck expands packaging plant to take on more vaccines. Story
CRO News
> Abbott, Syngene to open first R&D nutrition center in India. Item
> Synexus grabs Osteomed as its interest in Poland grows. Story
> What did the top CRO CEOs earn last year? Article
> Parexel experiences huge revenue and backlog growth in Q3. More
Vaccines News
> 'Designer' lymph nodes could boost cancer vaccines. Story
> Japan OKs Sanofi's inactivated polio vaccine. News
> Mucosis nasal flu vaccine shows positive results in animals. Report
> Ampligen-FluMist nasal trial begins. Article
And Finally... The Netherlands' Medical Brands gained European Class IIa Medical device status for its cranberry capsules as a treatment for bladder and urinary tract infections. The company supported its claim with clinical studies showing the product actually did its job. What's more, it is the first capsule to be sold as an over-the-counter medical device across Europe. Release